Exelixis (NASDAQ: EXEL) and Cleveland BioLabs (NASDAQ:CBLI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.
This table compares Exelixis and Cleveland BioLabs’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Exelixis has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500. Comparatively, Cleveland BioLabs has a beta of -0.59, suggesting that its share price is 159% less volatile than the S&P 500.
Earnings and Valuation
This table compares Exelixis and Cleveland BioLabs’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Exelixis||$452.48 million||12.89||$154.22 million||$0.51||38.51|
|Cleveland BioLabs||$1.95 million||14.66||-$9.70 million||N/A||N/A|
Exelixis has higher revenue and earnings than Cleveland BioLabs.
Institutional and Insider Ownership
77.8% of Exelixis shares are owned by institutional investors. Comparatively, 4.3% of Cleveland BioLabs shares are owned by institutional investors. 4.8% of Exelixis shares are owned by insiders. Comparatively, 2.0% of Cleveland BioLabs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for Exelixis and Cleveland BioLabs, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Exelixis currently has a consensus price target of $33.56, suggesting a potential upside of 70.85%. Given Exelixis’ higher possible upside, research analysts clearly believe Exelixis is more favorable than Cleveland BioLabs.
Exelixis beats Cleveland BioLabs on 10 of the 11 factors compared between the two stocks.
Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited, and Invenra, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
About Cleveland BioLabs
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.